CG Invites Co., Ltd. (KOSDAQ:083790)
966.00
+9.00 (0.94%)
Sep 9, 2026, 3:30 PM KST
CG Invites Revenue
CG Invites had revenue of 4.61B KRW in the quarter ending June 30, 2026, with 23.85% growth. This brings the company's revenue in the last twelve months to 30.11B, up 185.45% year-over-year. In the year 2025, CG Invites had annual revenue of 27.39B with 277.64% growth.
Revenue (ttm)
30.11B
Revenue Growth
+185.45%
P/S Ratio
2.47
Revenue / Employee
424.08M
Employees
71
Market Cap
74.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.39B | 20.14B | 277.64% |
| Dec 31, 2024 | 7.25B | 2.37B | 48.67% |
| Dec 31, 2023 | 4.88B | 557.33M | 12.90% |
| Dec 31, 2022 | 4.32B | -38.05B | -89.80% |
| Dec 31, 2021 | 42.38B | 12.15B | 40.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| ST Pharm | 386.46B |
| Sam Chun Dang Pharm. | 259.90B |
| BINEX | 157.28B |
| Oscotec | 144.18B |
| Mezzion Pharma | 8.43B |